Can I now get contraception from my pharmacist without seeing a GP?

From January 2027, yes — for initiation or resupply of oral hormonal contraception, pharmacists in participating states and territories will be able to prescribe. However, pharmacists cannot prescribe IUDs or hormonal implants (long-acting reversible contraception, or LARC). If you've been on your current oral method for a while and just need a resupply, a pharmacy consultation is reasonable. If you haven't reviewed your contraceptive method recently, or you're interested in more effective long-acting options, a GP appointment is still the right call.

Is it safe to treat a UTI at a pharmacy without seeing a GP?

For uncomplicated UTIs — burning on urination, frequency, no fever, no back pain, no signs of kidney involvement — pharmacy-based assessment and treatment is clinically defensible and already common in many states. A urine dipstick or mid-stream urine (MSU) test helps confirm before treatment. If symptoms don't resolve in 2–3 days, recur within a month, or include fever or loin pain, see a GP: those features suggest either resistance, a complicated UTI, or something other than a UTI.

Pharmacy UTI and contraception prescribing expands to all women from January

From January 2027, all Australian women will be able to access treatment for uncomplicated UTIs and initiate or resupply hormonal contraception at a community pharmacy — without a GP appointment. The Federal Government announced the expansion of its pharmacy prescribing pilot on 26 October 2026, seven months into a 12-month program that originally covered only concession card holders. The expansion is subject to state and territory rules.

For the woman who has spent three hours in a bulk billing queue with a UTI she has had three times before: this is the policy designed with you in mind.

What the trial covers and who it reaches

The 12-month pilot covers two specific areas:

Uncomplicated UTIs in women: assessment, urine testing, and trimethoprim or cephalexin prescribing
Hormonal contraception: initiation of a new method or resupply of an existing one

Federal Health and Ageing Minister Mark Butler said the trial has already benefited more than one million women and that the expansion aims to “make it easier for women to get care that fits into their lives.” The Government estimates about 900,000 additional women could benefit under the expanded program, depending on state-level regulatory frameworks. More than 8,000 women currently visit a community pharmacy each month for uncomplicated UTI treatment nationally.

The RACGP concerns — named clearly

RACGP President Dr Michael Wright described the expansion as “putting politics ahead of patient safety.” That is pointed language, and worth examining rather than dismissing.

Professor Danielle Mazza from Monash University’s General Practice department gave the most specific clinical concern: there is currently no rigorous Australian data on the safety and quality of pharmacy-initiated contraception prescribing. The pilot was expanded before evaluation of the original cohort. The decision to broaden access before results are in is the core of the evidence concern.

Professor Mazza’s second concern is about long-acting reversible contraception (LARC). Pharmacies can prescribe oral hormonal contraception. They cannot prescribe IUDs or hormonal implants — the most effective reversible methods available. The risk is that some women will choose oral contraception over a LARC option simply because the pharmacy is easier to access, rather than because oral contraception is the better clinical fit for them. Oral contraceptive failure rates (with typical use) are substantially higher than those for IUDs or implants.

That’s a real clinical trade-off, and it’s not captured in the access framing.

Both-and: holding the tension

The access argument is not empty. Women in rural and regional areas, women without a regular GP, women in low-income households who need contraception urgently — the expansion addresses a genuine gap in the current system. UTI management in particular has a well-established evidence base, and delay in treatment is associated with symptom escalation and avoidable antibiotic courses later.

The evidence concern is also not empty. Pharmacy prescribing for hormonal contraception is a different clinical task from UTI management. It involves a medication history, contraindication screening (migraine with aura, cardiovascular risk factors, smoking over 35), and — ideally — a conversation about whether oral contraception is actually the best method for that woman. General practice is built around that conversation. Pharmacies are not, at least not yet.

The Pharmacy Guild’s Professor Trent Twomey described the decision as “giving women more choice in accessing primary healthcare.” Choice only functions as a benefit when the options are roughly equivalent in quality. The LARC gap makes them unequal in one specific dimension that matters for long-term reproductive health.

2 cents: two scenarios, two different calls

For UTIs: if you have had an uncomplicated UTI before and this one fits the pattern exactly — burning on urination, frequency, no fever, no back or loin pain — pharmacy management from January is clinically reasonable. Get the urine dipstick done. If anything is different, see your GP.

For contraception: if you are on an established oral method and just need a resupply, a pharmacy consultation from January is likely fine. If you have not reviewed your contraceptive method in the past year or two, or you are starting contraception for the first time, a conversation with your GP is worth the time — particularly if a long-acting method might be a better fit for your life. The pharmacy expansion doesn’t make LARC any more accessible. That gap is still a GP appointment.

Verdict: maybe — the access gain is real; the LARC gap and the pre-expansion evidence base matter.